Table 1

Pharmacokinetics of rhEPO and rhNEPO in plasma and CSF after intravenous administration of a single dose of 500 µg of each protein in rats. The quantification of EPO derivatives were carried out by sandwich ELISA [1].

Pharmacokinetics

rhEPO

rhNEPO


Plasma 1

t1/2α (h) a

1.7

±

0.1

0.4

±

0.1

t1/2β (h) b

12.3

±

1.0

8.9

±

0.4

CSF 2

tCSF(min)c

30

5


a t1/2α, distribution half-life; b t1/2β, elimination half-life; c time to reach CSF after administration of EPO derivatives. 1Distribution and elimination half-lives and their corresponding standard deviations were obtained using a bi-compartmental pharmacokinetic model. 2 The tCSF refers to the first time point in which EPO derivatives were detected in CSF, and for this reason standard deviations were not considered.

Etcheverrigaray et al. BMC Proceedings 2011 5(Suppl 8):P3   doi:10.1186/1753-6561-5-S8-P3

Open Data